Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 4, 2024
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working GroupM F Mosele, C B Westphalen, A Stenzinger, et al.Journal of Cancer Research and Clinical Oncology|July 25, 2023
Early clinical trial unit tumor board: a real-world experience in a national cancer networkL Weiss, K Dorman, M Boukovala, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2020
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working GroupF Mosele, J Remon, J Mateo, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 26, 2024
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug developmentC B Westphalen, D Martins-Branco, J R Beal, et al.European Journal of Cancer (Oxford, England : 1990)|February 15, 2021
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' methodM Haas, D T Waldschmidt, M Stahl, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2024
ESMO Recommendations on clinical reporting of genomic test results for solid cancersJ van de Haar, P Roepman, F Andre, et al.ESMO Open|February 5, 2022
Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 studyS F Kruger, A Lohneis, A Abendroth, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2025
ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practiceC B Westphalen, L Boscolo Bielo, P Aftimos, et al.ESMO Open|February 27, 2026
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitorsE S M van Aken, S M O'Cathail, A K Gandhi, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 22, 2024
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancerM Ambrosini, B Rousseau, P Manca, et al.Pageof 4